Dermatonics

41 days ago

Regarding prolific lying: when did Stuart Ashman start being even more honest about how the June placing cash would be spent?

Bearded Geordie poltroon Stuart Ashman says without citing one actual example that I am a “prolific liar.” The overpaid and under-delivering CEO of Skinbiotherapeutics (SBTX) thinks that he always tells the truth. Let’s rewind to June 16th when shareholders were 10% diluted in a £4.2 million placing.

49 days ago

Stuart Ashman and a new rodent interview – surely AIM Regulation cannot allow this?

Stuart Ashman, the incompetent in charge at Skinbiotherapeutics (SBTX) recorded a podcast with the sycophantic poltroon Lemming yesterday in which he made statements which surely AIM Regulation must be all over. This is just not the way a CEO should conduct himself, even if the audience is only 23, as the maths just does not stack up.

51 days ago

Letter to the FCA and AIM Regulation: April to July 2025 you must launch a formal enquiry into Skinbiotherapeutics

I have now written to both regulators demanding a full enquiry into Stuart Ashman and Skin biotherapeutics (SBTX) as , at the very least , they have broken AIM Rule 10 at worse they have done a placing at a false price because of non disclosure to the wider market of adverse trading performance. In the wake of December 5 prelims there now needs to be a full formal enquiry

52 days ago

Skinbiothereapeutics final results to 30 June 2025: a curate’s egg and, natch, IFRS breaches

Skinbiotherapeutics (SBTX) published its final audited results for the twelve months to 30 June 2025 yesterday. FTSE 100 Companies operating across the world with billions of pounds of sales get their numbers out within three months. Skins took almost twice as long despite having just seven, all UK based, subsidiaries and 34 employees.

85 days ago

Skinbiotherapeutics and the rumoured Broker forecasts for Croda

Our in house bien pensant PL appears to have stumbled on forecasts from credible tier 1 brokers for how much revenue Croda (CRDA) will make from sales of the Skinbiotherapeutics (SBTX) product Zenakine. The source of this is, PL says, AI so it may be hogwash but it, perhaps, raises two critical points.

86 days ago

Explaining IFRS and Revenue Recognition to a Lemming re Skinbiotherapeutics

In an attempt to polish the turd which was the failure of Skinbiotherapeutics (SBTX) to ‘fess that it would miss revenue forecasts for the year to June 30 2025 by a country mile before doing a placing on 16 June, comrade Lemming makes an excuse in the comments section on this website which fails to appreciate IFRS Revenue recognition Rules.

583 days ago

Tom Winnifrith Bearcast: Skinbiotherapeutics does not impress this shareholder with its dissembling Dermatonics trading statement

I start with Wales and how not to make it richer. Then I look at Dave Lenigas run Pennpetro (PPP), UK Oil & Gas (UKOG), Helium One (HE1), Futura Medical (FUM) and Skinbiotherapeutics (SBTX).